<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A placebo-controlled, randomized, double-blind study was conducted to assess the efficacy and safety of pentoxifylline in 80 patients with symptoms of vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Efficacy was assessed using neuropsychologic tests </plain></SENT>
<SENT sid="2" pm="."><plain>With regard to the primary efficacy criteria, absolute changes in the active treatment group were more pronounced in both the protocol and endpoint analysis than in the placebo group </plain></SENT>
<SENT sid="3" pm="."><plain>Compared with the placebo group, differences were statistically significant for the active treatment group </plain></SENT>
<SENT sid="4" pm="."><plain>Similar changes were reported in a post-hoc defined subgroup of patients displaying "stepwise deterioration," an essential criterion of multi-<z:mpath ids='MPATH_124'>infarct</z:mpath> <z:hpo ids='HP_0000726'>dementia</z:hpo> (MID) </plain></SENT>
<SENT sid="5" pm="."><plain>Medication was generally well-tolerated </plain></SENT>
<SENT sid="6" pm="."><plain>The present study shows that pentoxifylline is suitable for the symptomatic treatment of vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>